CDC's State Biomonitoring Recompete Has Exactly Six Slots and All Six Are Occupied

The most useful thing you can do with a forecasted federal opportunity is arithmetic. CDC posted CDC-RFA-EH-27-0074, the State Biomonitoring Cooperative Agreement, as a forecast on September 22, 2026. The record lists 6 expected awards at $750,000 to $900,000 each, cooperative agreement instrument, no cost sharing, close date TBD.

Multiply it out: six awards in that band is $4.5 million to $5.4 million per year.

The cycle this replaces awarded $5 million annually across six recipients from September 2024 through 2027. So despite one widely circulated federal opportunity tracker listing this program at $15 million — which is very likely the three-year total, not the annual figure — the honest read of the forecast is that CDC is recompeting a flat program with the same number of slots.

That changes the strategy entirely. This is not an expansion you can grow into. It is a fixed six-chair competition where every chair currently has someone in it.

Who holds the six chairs

The 2024 competition selected:

Note what Arizona did. One award, four states. The Four Corners consortium is a long-running structure — CDC has funded versions of it going back more than a decade — and it exists precisely because four states with individually thin laboratory capacity can assemble one competitive application that none of them could file alone.

That is the single most important strategic fact in this program. Six awards does not mean six jurisdictions. It means six applications, and one of them already covers four states. The consortium is the documented path into a program with no open slots.

What the program actually buys

The purpose language is specific: support state, local, tribal, and territorial public health laboratories in conducting high-quality biomonitoring and assessing human exposure to environmental chemicals within their jurisdictions. The 2024 cycle added a focus on building or leveraging existing capacity to assess exposure in communities unequally affected by exposure.

Biomonitoring means measuring chemicals and their metabolites in human biological specimens — blood, urine, serum — to establish internal dose rather than estimated environmental concentration. It is the difference between "the well water tested at 12 parts per trillion" and "the people who drink from that well carry this much in their blood."

The current awardees' work shows what a fundable project looks like. The Four Corners consortium is assessing heavy metal exposures in rural communities and investigating PFAS exposure in occupations at elevated risk, including firefighters. That combination — a legacy contamination class, a named geographic population, and an occupational cohort with a plausible exposure pathway — is the template.

The eligibility trap

Here is where applicants waste months. The forecast lists an extraordinarily broad eligibility set: state governments, county and city governments, special district governments, independent school districts, public and private institutions of higher education, federally recognized tribal governments, other tribal organizations, public and Indian housing authorities, and nonprofits with and without 501(c)(3) status.

Read that list and a mid-sized nonprofit could reasonably conclude it is eligible. Technically it is. Practically it is not competitive, and the reason is not written in the eligibility section.

This is a laboratory capability program. The National Biomonitoring Network, established in 2018, is an interconnected system of government laboratories organized into a tiered membership structure based on analytical capabilities and experience — 20 state public health laboratories as of mid-2021. Membership requires documented method validation, verified technical competency, independent certification against CLIA, CAP, or ISO standards, and demonstrated success in external quality assessment programs at target-population concentration levels.

That last clause is the barrier. Measuring PFAS at parts-per-billion in an industrial sample is routine analytical chemistry. Measuring it in human serum at the concentrations found in the general population requires high-sensitivity LC-MS/MS or ICP-MS instrumentation, validated low-level methods, and proficiency-tested staff. A laboratory that cannot pass EQA at population concentrations cannot produce data CDC will accept, regardless of how compelling the community exposure narrative is.

The broad eligibility list is real but misleading. The functional eligibility requirement is an accredited laboratory with validated trace-level human-specimen methods, or a formal partnership with one.

The capacity gap is the opportunity

CDC has funded state biomonitoring capacity through cooperative agreements since 2001, and the resulting landscape is uneven by design. Capability varies sharply across states because of differences in land-use practices, state and local law, and — most of all — available resources. Roughly 20 of 50 state public health laboratories are network members. That leaves a large majority of the country without the analytical capacity to answer basic exposure questions about its own population.

Look at the current six against that map. Five are in the Northeast and Upper Midwest. The sixth covers the interior Southwest. Uncovered: the entire Southeast, the Gulf Coast petrochemical corridor, Texas, Appalachia, the Pacific Northwest, California, Alaska and Hawaii, and the territories.

Several of those regions carry the most acute exposure questions in the country — refinery emissions along the Houston Ship Channel and in Louisiana's river parishes, coal ash impoundments across the Southeast, arsenic and manganese in Appalachian private wells, subsistence-diet contaminant exposure in Alaska Native communities. If CDC intends the network to reflect national exposure burden rather than existing laboratory infrastructure, the strongest applications from those regions are not competing on equal footing with incumbents. They are competing on a gap the program itself has documented.

What to do during the forecast window

A forecast with a TBD close date typically converts to a full announcement in three to six months. One tracker has circulated an anticipated deadline around April 19, 2027; treat that as unconfirmed and useful only for planning. Here is what the interval is for.

Resolve the laboratory question first, and honestly. Pull your state public health laboratory's current method validation list and EQA performance for the analyte classes you want to measure. If you cannot document population-level proficiency for metals or PFAS, your near-term project is not this application — it is method validation and EQA enrollment, which takes a year or more. Starting that in October 2026 puts you in position for the cycle after this one.

Build the consortium before the announcement, not after. Arizona's model is the demonstrated way a lower-capacity region wins one of six slots. A consortium application requires a lead applicant with the strongest lab, subaward agreements, a shared data-management plan, harmonized specimen collection protocols, and a governance structure. Published lessons from the original Four Corners implementation document exactly how much of that work is administrative rather than scientific. None of it can be assembled in six weeks.

Pick an exposure question CDC has not funded. The incumbents own heavy metals in rural Southwest communities and occupational PFAS in firefighters. Duplicating that from a weaker laboratory base is the losing application. Owning something specific and unfunded — subsistence food-chain contaminants, agricultural fumigant metabolites, petrochemical-adjacent volatile organics, disinfection byproducts in systems under consent decree — is how you beat a program the incumbents already understand.

Define the community partnership at the specimen level. Biomonitoring requires people to give blood and urine. The applications that fail at implementation are the ones that solve the chemistry and assume the recruitment. Document who enrolls participants, how consent works, how results are returned to individuals, and what the community's role is in interpreting them. Specimen access is the operational bottleneck, and reviewers who have watched awards underperform know it.

Ask CDC the three forecast-stage questions. Whether the $750,000-to-$900,000 band is direct or total costs. Whether consortium applications are encouraged, permitted, or counted against the six. And whether CDC has stated intentions about geographic or capacity-tier coverage. Program staff are more candid before an announcement locks than at any other point in the cycle.

The general lesson holds well beyond biomonitoring. A flat-funded federal program with a fixed slot count and fully occupied seats is not won by writing a better application in the sixty days after the announcement publishes. It is won by changing your eligibility position — building lab capability, forming a consortium, claiming an unclaimed exposure question — during the months when nobody else is paying attention to a record marked "Forecasted." If you want those records surfaced while the window is still open, Granted tracks forecasted opportunities alongside live ones instead of waiting for a deadline to exist.